Marianne Henderson joins the Scientific Advisory Board of CloudLIMS
CloudLIMS, a Laboratory Information Management company specialised data management solutions for biorepositories, has announced that Ms Marianne Henderson has joined its Scientific Advisory Board (SAB), contributing her rich experience in the biobanking to the company’s informatics solutions.
Ms Henderson currently serves as senior advisor on biobanking to the National Cancer Institute’s (NCI) Center for Global Health and the senior advisor for Division Resources, Division of Cancer Epidemiology and Genetics (DCEG) she is a founding member of the NCI Biospecimen Coordinating Committee and participated in the development and revision of the first and second editions of NCI’s Best Practices for Biospecimen Resources.
From 1999-2015, she served as Chief of DCEG's Office of Division Operations and Analysis. Since 1999, she has been a member of the International Society for Biological and Environmental Repositories (ISBER) and served as ISBER President 2011–2012. She is currently the chair of the ISBER Organising Advisory Committee. Ms Henderson is actively involved in human biospecimen management process improvements in processing, handling, technology transfer, and repository automation.
She also served as a member for several biobank groups including Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)–Large Prospective Cohorts Scientific and Ethical Advisory Board, and the BBMRI.se (Sweden Node) Advisory Board. She is a current member of the US Interagency Working Group on Scientific Collections; Marble Arch, a biobanking think tank; and Chair of the Education and Training subcommittee and Steering committee member of the International Agency on Cancer’s Low and Middle Income Country Biobank and Cohort Building Network (BCNet).
‘We are honoured to have Ms Marianne Henderson on our distinguished team of scientific advisors and look forward to her invaluable guidance,’ said Arun Apte, CEO at CloudLIMS. ‘Her experience in the field of biobanking will add significant value to our operations as we continue to expand our services in the market.’